Table 2.
Summary of included studies (overall clinical success rate, per-indication clinical success rate, and overall over-the-scope clip-related adverse event rate)
|
Ref. |
Year |
Type of study |
Country |
Patients (n) |
Overall clinical success rate (%) |
Follow-up (wk) |
Adverse events, n (%) | ||||||
|
Indications |
Total | ||||||||||||
| Fistula | Bleeding | Perforation | Leak | ER | Stent fixation | ||||||||
| Seebach et al[15] | 2010 | Case series Retrospective | Switzerland | 7 | - | - | 57.1 | - | - | - | 57.1 | 10-42 | NR |
| Kirschniak et al[2] | 2007 | Retrospective | Germany | 11 | - | 100 | 100 | - | 100 | - | 100 | 1-5 | 0.0 |
| Mudumubi et al[16] | 2014 | Retrospective | International1 | 12 | - | - | - | - | - | 83.3 | 83.3 | 3-40 | 0.0 |
| Sandmann et al[17] | 2011 | Case series Retrospective | Germany | 11 | 100 | - | 100 | 66 | 100 | - | 90.9 | 12.7 | NR |
| Albert et al[18] | 2011 | Retrospective | Germany | 19 | - | 57.1 | - | 66.7 | - | - | 63.2 | 1-68 | 0.0 |
| Repici et al[19] | 2009 | Case series Retrospective | Italy | 9 | - | 100 | - | - | 100 | - | 100 | 4-12 | 0.0 |
| Donatelli et al[20] | 2016 | Retrospective | International2 | 45 | 36.7 | - | 100 | - | - | - | 57.8 | 36-100 | 0.0 |
| Maekawa et al[21] | 2015 | Prospective | Japan | 12 | - | - | - | - | 91.7 | - | 91.7 | NR | 0.0 |
| Gautier et al[22] | 2015 | Retrospective Multi-center | France | 17 | 11.8 | - | - | - | - | - | 11.8 | 12 | NR |
| Nishiyama et al[23] | 2013 | Retrospective | Japan | 23 | 75 | 77.8 | 75 | - | 100 | - | 82.6 | 2-8 | 0.0 |
| Voermans et al[24] | 2012 | Prospective Multi-center | Netherlands | 36 | - | - | 88.9 | - | - | - | 88.9 | 1-26 | 0.0 |
| Lee et al[26] | 2017 | Prospective Multi-center | Korea | 19 | 25 | - | 100 | 83.3 | 100 | - | 73.7 | 72 | 0.0 |
| Angsuwatcharakon et al[27] | 2016 | Retrospective | Thailand | 6 | - | - | 83.3 | - | - | - | 83.3 | NR | NR |
| Arezzo et al[28] | 2012 | Case series Prospective | Italy | 14 | - | - | - | 85.7 | - | - | 85.7 | 16 | 0.0 |
| Schlag et al[29] | 2013 | Prospective | Germany | 6 | - | - | 100 | - | - | - | 100 | 4-12 | 0.0 |
| Disibeyaz et al[30] | 2012 | Case series Retrospective | Turkey | 9 | 33.3 | - | 100 | 60 | - | - | 55.6 | NR | 0.0 |
| Gubler et al[31] | 2012 | Case series Prospective | Switzerland | 14 | - | - | 85.7 | - | - | - | 85.7 | 4-48 | NR |
| Singhal et al[32] | 2014 | Case Series Prospective | United States | 10 | 90 | - | - | - | - | - | 90 | 7 | 0.0 |
| Mennigen et al[33] | 2013 | Case series Retrospective | Germany | 14 | 71.4 | - | 100 | 83.3 | - | - | 78.6 | 1-68 | 0.0 |
| Faehndrich et al[34] | 2015 | Retrospective | Germany | 17 | - | - | - | - | 94.1 | - | 94.1 | NR | 0.0 |
| Schmidt et al[4] | 2015 | Prospective Multi-center RCT | International3 | 24 | - | - | - | - | 75 | - | 75 | 4 | 2 (8.3) |
| Guo et al[35] | 2015 | Retrospective | China | 23 | - | - | - | - | 100 | - | 100 | 4-24 | 2 (8.7) |
| Correia et al[36] | 2014 | Case series Prospective | Portugal | 6 | 80 | - | 100 | - | - | - | 83.3 | NR | 0.0 |
| Goenka et al[37] | 2017 | Prospective | India | 12 | 66 | 100 | 100 | - | - | - | 91.7 | 4-8 | 0.0 |
| Surace et al[38] | 2011 | Prospective | Italy | 19 | 73.7 | - | - | - | - | - | 73.7 | 32 | 1 (5.3) |
| Kochhar et al[39] | 2017 | Case series Prospective | United States | 12 | - | - | - | 66.7 | - | - | 66.7 | 60 | 1 (8.3) |
| Manta et al[40] | 2017 | Prospective | Italy | 76 | - | - | - | 80.3 | - | - | 80.3 | NR | 0.0 |
| Parodi et al[41] | 2010 | Prospective | Italy | 10 | 80 | - | 100 | 50 | - | - | 80.0 | NR | 0.0 |
| Manta et al[42] | 2011 | Case series Retrospective | Italy | 12 | 87.5 | - | - | 75 | - | - | 83.3 | 4 | 0.0 |
| Honegger et al[43] | 2017 | Retrospective Cohort | Switzerland | 203 | 29.8 | 77.4 | 86.1 | 33.3 | - | 66.7 | 63.1 | 4 | 6 (3.0) |
| Manno et al[44] | 2015 | Retrospective | International4 | 40 | - | 100 | - | - | - | - | 100 | 4 | 0.0 |
| Richter-Schrag et al[45] | 2016 | Retrospective | Germany | 100 | - | 78 | - | - | - | - | 78 | NR | NR |
| Aepli et al[46] | 2016 | Retrospective | Switzerland | 24 | - | - | - | - | 87.5 | - | 87.5 | NR | 4 (16.7) |
| Law et al[48] | 2015 | Retrospective Multi-center | United States | 47 | 53.2 | - | - | - | - | - | 53.2 | 26 | 0.0 |
| Farnik et al[3] | 2015 | Retrospective Multi-center | International5 | 34 | - | - | 100 | 56.3 | - | - | 70.5 | 39 | 0.0 |
| Jacobsen et al[49] | 2012 | Retrospective | United States | 10 | 0 | - | 100 | 80 | - | - | 70.0 | 12 | 0.0 |
| Haito-Chavez et al[50] | 2014 | Retrospective Multi-center | International6 | 161 | 42.9 | - | 90 | 73.3 | - | - | 60.2 | 18 – 30 | 0.0 |
| Winder et al[51] | 2016 | Retrospective | United States | 28 | 77.2 | - | - | 100 | - | - | 82.1 | 19 | 0.0 |
| Sulz et al[52] | 2014 | Case series Prospective | Switzerland | 19 | 54.5 | 100 | - | 66.7 | - | 100 | 63.1 | NR | 0.0 |
| Magdeburg et al[53] | 2015 | Prospective | Germany | 43 | - | - | 97.8 | - | - | - | 97.8 | NR | 3 (7.0) |
| Wedi et al[54] | 2016 | Retrospective | France | 84 | 100 | 89.3 | 57.1 | - | 100 | - | 89.3 | NR | 2 (2.4) |
| Keren et al[55] | 2014 | Case series Prospective | Israel | 26 | - | - | - | 80.8 | - | - | 80.8 | NR | 0.0 |
| Raithel et al[14] | 2017 | Retrospective Multi-center | Germany | 34 | - | - | 74.1 | 85.7 | - | - | 76.5 | NR | 3 (8.8) |
| Kobara et al[56] | 2017 | Retrospective Multi-center | Japan | 58 | 83.3 | 83.3 | - | 85.7 | - | - | 84.5 | 4+ | 1 (1.8) |
| Hagel et al[57] | 2012 | Case series Prospective | Germany | 17 | - | - | 64.7 | - | - | - | 64.7 | 4 | NR |
| Nasa et al[58] | 2016 | Case series Retrospective | India | 7 | 80 | 100 | 100 | - | - | - | 85.7 | 45 | NR |
| Skinner et al[6] | 2014 | Retrospective | United States | 12 | - | 83.3 | - | - | - | - | 83.3 | 10 – 30 | 0.0 |
| Al-Bawardy et al[59] | 2017 | Retrospective | United States | 7 | - | - | - | - | 100 | - | 100 | 1 – 86 | 0.0 |
| Sarker et al[60] | 2014 | Retrospective | United States | 8 | - | - | - | - | 100 | - | 100 | 4 – 52 | 0.0 |
| Mangiavillano et al[61] | 2016 | Retrospective | Italy | 20 | - | - | 90 | - | - | - | 90 | 12 | NR |
| Aiolfi et al[62] | 2014 | Retrospective | Italy | 7 | - | - | - | 85.7 | - | - | 85.7 | NR | NR |
| Manta et al[5] | 2013 | Case series Multi-center | Italy | 30 | - | 90 | - | - | - | - | 90 | 1 – 4 | 0.0 |
| Mangiafico et al[63] | 2017 | Case series Prospective | International7 | 7 | 100 | - | - | - | - | - | 100 | 2 – 8 | 0.0 |
| Niland et al[64] | 2017 | Retrospective | United States | 14 | 21.4 | - | - | - | - | - | 21.4 | 26 | 0.0 |
| Schmdtt et al[4] | 2018 | Prospective RCT | International8 | 33 | - | 84.8 | - | - | - | - | 84.8 | 4 | 0.0 |
| Heinrich et al[65] | 2017 | Case series Retrospective | Switzerland | 5 | 100 | - | - | - | - | - | 100 | 46 – 269 | 0.0 |
| Prosst et al[66] | 2015 | Prospective | Germany | 20 | 90 | - | - | - | - | - | 90 | 24 | 0.0 |
| Mizrahi et al[67] | 2016 | Prospective | United States | 51 | 35.3 | 75 | 75 | 50 | - | 50 | 49.0 | 48 | NR |
| Kirschniak et al[68] | 2011 | Retrospective | Germany | 46 | 37.5 | 93 | 100 | - | - | - | 84.8 | 1 – 2 | 0.0 |
| Mennigen et al[69] | 2015 | Retrospective | Germany | 10 | 70 | - | - | - | - | - | 70 | 22 – 75 | 0.0 |
| Wedi et al[70] | 2016 | Retrospective Case series | International9 | 6 | - | 100 | - | - | - | - | 100 | NR | NR |
| Baron et al[71] | 2012 | Retrospective Multi-center | United States | 43 | 67.9 | 100 | 80 | 33.3 | - | - | 72.1 | 4 – 11 | 2 (4.7) |
| Lamberts et al[72] | 2017 | Retrospective | Germany | 75 | - | 65.3 | - | - | - | - | 65.3 | NR | NR |
| Soetikno et al[73] | 2016 | Case series Retrospective | International10 | 5 | - | 100 | - | - | - | - | 100 | 60 | 0.0 |
| Wedi et al[74] | 2017 | Retrospective | International11 | 100 | - | 86 | - | - | - | - | 73 | NR | NR |
| Chan et al[75] | 2014 | Case series Prospective | China | 9 | - | 77.8 | - | - | - | - | 77.8 | 8 | NR |
| Keen et al[76] | 2019 | Prospective | United Kingdom | 59 | - | 93.2 | - | - | - | - | 93.2 | 4 | NR |
| Horenkamp-Sonntag et al[77] | 2019 | Retrospective | Germany | 92 | - | 82.4 | 87.9 | - | - | - | 92.4 | 14 | NR |
| Manta et al[78] | 2019 | Retrospective Multi-center | Italy | 286 | - | 94.4 | - | - | - | - | 94.4 | 4 | NR |
| Mercky et al[79] | 2015 | Retrospective | France | 30 | 73.3 | - | - | - | - | - | 73.3 | 42 | 3 (10) |
| Monkemuller et al[80] | 2014 | Case series Retrospective | Germany | 16 | 50 | 100 | - | 0 | 100 | 100 | 75 | 44 | 0.0 |
| Bonino et al[81] | 2014 | Case series Prospective | Italy | 26 | 90 | - | 68.8 | - | - | - | 76.9 | NR | 0.0 |
| Christophorou et al[82] | 2015 | Retrospective Multi-center | France | 14 | 78.5 | - | - | - | - | - | 78.5 | NR | NR |
| Lunse et al[83] | 2019 | Retrospective | Germany | 9 | 66.7 | - | - | - | - | - | 66.7 | 8 | 0.0 |
| Mosquera-Klinger et al[84] | 2019 | Retrospective Case series | Columbia | 14 | 70 | 100 | 100 | - | - | 100 | 78.6 | 20 | 0.0 |
| Brander et al[25] | 2017 | Retrospective | United States | 67 | - | 70.1 | - | - | - | - | 70.1 | 4 | NR |
| Meier et al[47] | 2017 | Retrospective | Germany | 10 | - | - | - | - | 100 | - | 100 | 12 | 0.0 |
| Tashima et al[85] | 2017 | Prospective | Japan | 50 | - | - | - | - | 94 | - | 94 | 2 | 4 (8) |
| Khater et al[86] | 2017 | Retrospective | France | 11 | - | - | 81.2 | - | - | - | 81.2 | NR | 1 (9) |
| Asokkumar et al[87] | 2018 | Retrospective | International12 | 19 | - | 100 | - | - | - | - | 100 | NR | 0.0 |
| Morrell et al[88] | 2019 | Retrospective | United States | 117 | 50.8 | - | - | 75 | - | - | 61.2 | 22 | 0.0 |
| Kappelle et al[89] | 2018 | Prospective | Netherlands | 13 | - | - | - | - | 84.6 | - | 84.6 | 24 | 5 (38.4) |
| Wei et al[90] | 2019 | Retrospective | China | 26 | - | - | 100 | - | - | - | 100 | 4 | 0.0 |
| Golder et al[91] | 2019 | Retrospective | Germany | 100 | - | 75 | - | - | - | - | 75 | NR | 0.0 |
| Wedi et al[92] | 2018 | Retrospective Multi-center | Germany | 118 | - | 92.4 | - | - | - | - | 92.4 | 4 | NR |
| Total | 3025 | 55.8% | 86.0% | 85.3% | 72.6% | 92.8% | 80.0% | 78.4% | - | 2.1% | |||
| 347/622 | 1120/1303 | 399/468 | 284/391 | 205/221 | 16/20 | 2371/3025 | - | 40/194213 | |||||
1
Germany, United States.
2
France, Italy, India.
3
Switzerland, Germany.
4
Italy, United Kingdom.
5
Germany, Japan.
6
United States, Italy, Germany, Netherlands, Chile.
7
Italy, United Kingdom.
8
Germany, China, Switzerland.
9
Germany, France, Canada, United States.
10
United States, Singapore.
11
Germany, France, Canada, United States.
12
Singapore, Spain.
13
Over the scope clip-related adverse events were only reported for 1958 of 3041 patients (n = 65 studies). NR: Not reported; ER: Endoscopic resection; RCT: Randomized control trial.